HRP20170557T2 - Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21 - Google Patents
Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21 Download PDFInfo
- Publication number
- HRP20170557T2 HRP20170557T2 HRP20170557TT HRP20170557T HRP20170557T2 HR P20170557 T2 HRP20170557 T2 HR P20170557T2 HR P20170557T T HRP20170557T T HR P20170557TT HR P20170557 T HRP20170557 T HR P20170557T HR P20170557 T2 HRP20170557 T2 HR P20170557T2
- Authority
- HR
- Croatia
- Prior art keywords
- fibrosis
- compound
- preparation according
- kidney
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
Claims (15)
1. Spoj koji sadrži modificirani oligonukleotid koji se sastoji od nukleobazne sekvence i modifikacija:
AECSATCSAGTCSTGAUSAAGCSTAE;
pri čemu nukleozidi koje ne slijedi indeks su β-D-deoksiribonukleozidi, nukleozidi koje slijedi indeks "E" su 2'-MOE nukleozidi, nukleozidi koje slijedi indeks "S" su S-cEt nukleozidi; te pri čemu svaka internukleozidna veza je fosforotioatna internukleozidna veza.
2. Spoj prema zahtjevu 1, naznačen time da se sastoji od navedenog modificiranog oligonukleotida.
3. Farmaceutski pripravak naznačen time da sadrži spoj prema zahtjevu 1 ili zahtjevu 2 i farmaceutski prihvatljiv nosač.
4. Spoj prema zahtjevu 1 ili zahtjevu 2 ili farmaceutski pripravak prema zahtjevu 3, naznačen time da je za uporabu za terapiju.
5. Spoj ili pripravak prema zahtjevu 4, naznačen time da je za uporabu za liječenje fibroze.
6. Spoj prema zahtjevu 1 ili zahtjevu 2 ili farmaceutski pripravak prema zahtjevu 3, naznačen time da je za uporabu u postupku liječenja, prevencije ili odgađanja početka bolesti povezane s miR-21 koji se sastoji od davanja spoja ili pripravka subjektu koji ima bolest povezanu s miR-21, pri čemu je bolest fibroza, kao što je fibroza odabrana od fibroze bubrega, fibroze pluća, fibroze jetre, srčane fibroze, fibroze kože, staračke fibroze, fibroze slezene, sklerodermije, te fibroze nakon transplantacije.
7. Spoj ili pripravak prema zahtjevu 6, naznačen time da fibroza je fibroza bubrega.
8. Spoj ili pripravak prema zahtjevu 7, naznačen time da:
a) fibroza bubrega je prisutna kod subjekta koji pati od bolesti izabrane od glomeruloskleroze, tubulointerstitialne fibroze, IgA nefropatije, intersticijske fibroze/tubularne atrofije; kroničnog oštećenja bubrega, glomerularne bolesti, glomerulonefritisa, dijabetes melitusa, idiopatske fokalne segmentne glomeruloskleroze, membranske nefropatije, kolapsne glomerulopatije, kronične recidivirajuće infekcije bubrega, te od zadnjeg stadija bubrežne bolesti; ili
b) fibroza bubrega proizlazi iz akutne ili ponavljajuće traume bubrega.
9. Spoj ili pripravak prema bilo kojem od zahtjeva 6-8, naznačen time da postupak obuhvaća odabir subjekta koji ima povišenu ekspresiju miR-21 u jednom ili više tkiva.
10. Spoj ili pripravak prema bilo kojem od zahtjeva 6-9, naznačen time da postupak obuhvaća davanje barem jednog terapeutskog sredstva odabranog od protu-upalnog sredstva, imunosupresivnog sredstva, antidijabetičkog sredstva, digoksina, vazodilatatora, inhibitora angiotenzin II konvertirajućeg enzima (ACE), blokatora angiotenzinskih II receptora (ARB), blokatora kalcijevih kanala, izosorbid dinitrata, hidralazina, nitrata, hidralazina, beta-blokatora, natriuretskih peptida, heparinoida, te inhibitora faktora rasta vezivnog tkiva.
11. Spoj ili pripravak prema zahtjevu 10, naznačen time da postupak obuhvaća davanje barem jednog inhibitora ACE.
12. Spoj ili pripravak prema zahtjevu 11, naznačen time da se inhibitor ACE bira iz skupine koju čine kaptopril, enalapril, lizinopril, benazepril, kinapril, fosinopril, te ramipril.
13. Spoj ili pripravak prema zahtjevu 10, naznačen time da postupak obuhvaća davanje barem jednog inhibitora ARB.
14. Spoj ili pripravak prema zahtjevu 13, naznačen time da se inhibitor ARB bira iz skupine koju čine kandesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, te eprosartan.
15. Spoj ili pripravak prema bilo kojem od zahtjeva 6-14, naznačen time da subjekt je čovjek.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478767P | 2011-04-25 | 2011-04-25 | |
| US201161565779P | 2011-12-01 | 2011-12-01 | |
| EP12718549.4A EP2702155B9 (en) | 2011-04-25 | 2012-04-25 | Microrna compounds and methods for modulating mir-21 activity |
| PCT/US2012/034880 WO2012148952A1 (en) | 2011-04-25 | 2012-04-25 | Microrna compounds and methods for modulating mir-21 activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20170557T1 HRP20170557T1 (hr) | 2017-06-16 |
| HRP20170557T2 true HRP20170557T2 (hr) | 2020-02-21 |
Family
ID=46025979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170557TT HRP20170557T2 (hr) | 2011-04-25 | 2017-04-06 | Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21 |
| HRP20210616TT HRP20210616T1 (hr) | 2011-04-25 | 2021-04-19 | Spojevi mikrornk i postupci za moduliranje aktivnosti mir-21 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210616TT HRP20210616T1 (hr) | 2011-04-25 | 2021-04-19 | Spojevi mikrornk i postupci za moduliranje aktivnosti mir-21 |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US9181547B2 (hr) |
| EP (3) | EP3933040A1 (hr) |
| JP (2) | JP6320292B2 (hr) |
| KR (2) | KR102055172B1 (hr) |
| CN (3) | CN113249381A (hr) |
| AU (4) | AU2012249851B2 (hr) |
| BR (1) | BR112013027187A2 (hr) |
| CA (2) | CA3165397A1 (hr) |
| CL (1) | CL2013003105A1 (hr) |
| CO (1) | CO6821889A2 (hr) |
| CY (1) | CY1120304T1 (hr) |
| DK (2) | DK2702155T3 (hr) |
| EA (1) | EA025894B1 (hr) |
| ES (2) | ES2868950T3 (hr) |
| HK (1) | HK1243130A1 (hr) |
| HR (2) | HRP20170557T2 (hr) |
| HU (2) | HUE031595T2 (hr) |
| IL (3) | IL229032B (hr) |
| LT (2) | LT2702155T (hr) |
| MX (5) | MX2013012452A (hr) |
| MY (2) | MY187685A (hr) |
| NZ (1) | NZ717921A (hr) |
| PH (1) | PH12013502199A1 (hr) |
| PL (2) | PL2702155T3 (hr) |
| PT (2) | PT3211082T (hr) |
| RS (1) | RS61775B1 (hr) |
| SG (1) | SG194636A1 (hr) |
| SI (2) | SI3211082T1 (hr) |
| TW (2) | TWI607016B (hr) |
| UA (1) | UA115652C2 (hr) |
| WO (1) | WO2012148952A1 (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2503738T3 (es) | 2004-11-12 | 2014-10-07 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| LT2702155T (lt) | 2011-04-25 | 2017-05-10 | Regulus Therapeutics Inc. | Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui |
| WO2013153082A1 (en) * | 2012-04-10 | 2013-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of nonalcoholic steatohepatitis |
| PH12023550488A1 (en) * | 2012-04-25 | 2024-06-24 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| SI2920304T1 (sl) | 2012-11-15 | 2019-06-28 | Roche Innovation Center Copenhagen A/S | Oligonukleotidni konjugati |
| SG11201508925WA (en) * | 2013-05-01 | 2015-11-27 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-122 |
| WO2015061536A1 (en) * | 2013-10-25 | 2015-04-30 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| KR101625755B1 (ko) | 2013-11-18 | 2016-05-30 | 울산대학교 산학협력단 | ｍｉＲＮＡ 스폰지 및 이의 용도 |
| WO2015113922A1 (en) * | 2014-01-30 | 2015-08-06 | Roche Innovation Center Copenhagen A/S | Poly oligomer compound with biocleavable conjugates |
| CN105734127A (zh) * | 2016-02-29 | 2016-07-06 | 上海中医药大学 | miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途 |
| WO2017187426A1 (en) * | 2016-04-29 | 2017-11-02 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| JP2020534015A (ja) | 2017-09-22 | 2020-11-26 | ユニヴァーシティ オブ ワシントン | 細胞分子のｉｎ ｓｉｔｕコンビナトリアル標識化 |
| CN108148911B (zh) * | 2018-03-02 | 2019-11-05 | 广州医科大学附属第二医院 | miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用 |
| CN112400020B (zh) | 2018-05-08 | 2024-11-19 | 莱古路斯治疗法股份有限公司 | 作为具有hcv抗病毒活性与降低的高胆红素血症副作用的mir-122抑制剂的galnac缀合的经修饰的寡核苷酸 |
| CN110747266A (zh) * | 2018-07-23 | 2020-02-04 | 深圳先进技术研究院 | miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用 |
| CN109880907A (zh) * | 2019-03-26 | 2019-06-14 | 中国人民解放军第八一医院 | 一种肝癌细胞侵袭转移的分子机制研究方法 |
| US11965162B2 (en) | 2020-04-16 | 2024-04-23 | The Johns Hopkins University | MicroRNA and inhibitors thereof and methods of treatment |
| WO2022165092A1 (en) * | 2021-01-29 | 2022-08-04 | Angion Biomedica Corp. | Methods for treatment of fibrotic diseases |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060008817A1 (en) * | 2000-12-08 | 2006-01-12 | Invitrogen Corporation | Methods and compositions for generating recombinant nucleic acid molecules |
| IL161100A0 (en) | 2001-09-28 | 2004-08-31 | Max Planck Gesellschaft | Identification of novel genes coding for small temporal rnas |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| ATE555118T1 (de) | 2003-08-28 | 2012-05-15 | Takeshi Imanishi | Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung |
| AU2005272816B2 (en) | 2004-08-10 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| ES2503738T3 (es) | 2004-11-12 | 2014-10-07 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| EP1838870A2 (en) | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
| US6995235B1 (en) | 2005-05-02 | 2006-02-07 | Univation Technologies, Llc | Methods of producing polyolefins and films therefrom |
| WO2007027894A2 (en) * | 2005-08-29 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Antisense compounds having enhanced anti-microrna activity |
| EP1984381B1 (en) | 2006-01-27 | 2010-09-29 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| AU2007211082B2 (en) | 2006-01-27 | 2012-09-27 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| JP5198430B2 (ja) | 2006-04-03 | 2013-05-15 | サンタリス ファーマ アー／エス | ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物 |
| EP3502255A1 (en) * | 2006-04-03 | 2019-06-26 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition |
| KR101129509B1 (ko) | 2006-10-03 | 2012-04-13 | 알닐람 파마슈티칼스 인코포레이티드 | 지질 함유 조성물 |
| EP2476762B1 (de) | 2006-10-09 | 2014-01-08 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen |
| EP2104735A2 (en) | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| EP2118118B1 (en) | 2007-01-19 | 2017-09-27 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
| AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
| US20100261175A1 (en) | 2007-06-15 | 2010-10-14 | Exiqon A/S | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis |
| EP2176280B2 (en) | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| DK2205737T3 (da) * | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
| US8211867B2 (en) | 2007-10-29 | 2012-07-03 | Regulus Therapeutics Inc. | Targeting microRNAs for the treatment of liver cancer |
| US20110257244A1 (en) | 2008-01-18 | 2011-10-20 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof |
| EP2096171A1 (en) * | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| US8404659B2 (en) | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
| JP2012518997A (ja) * | 2009-02-26 | 2012-08-23 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 喫煙未経験者におけるマイクロｒｎａ、ならびに関連する材料および方法 |
| CA2765129A1 (en) * | 2009-06-08 | 2010-12-16 | Miragen Therapeutics | Chemical modification motifs for mirna inhibitors and mimetics |
| WO2011126842A2 (en) | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
| LT2702155T (lt) | 2011-04-25 | 2017-05-10 | Regulus Therapeutics Inc. | Mikro rnr junginiai ir būdai mir-21 aktyvumo moduliavimui |
| WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
| PH12023550488A1 (en) | 2012-04-25 | 2024-06-24 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| WO2013192576A2 (en) | 2012-06-21 | 2013-12-27 | Miragen Therapeutics | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
| CN104955950B (zh) | 2012-09-26 | 2019-04-26 | 米尔克斯治疗学公司 | 具有改善的脱靶特征谱的寡核苷酸 |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
-
2012
- 2012-04-25 LT LTEP12718549.4T patent/LT2702155T/lt unknown
- 2012-04-25 HU HUE12718549A patent/HUE031595T2/en unknown
- 2012-04-25 PH PH1/2013/502199A patent/PH12013502199A1/en unknown
- 2012-04-25 DK DK12718549.4T patent/DK2702155T3/en active
- 2012-04-25 MY MYPI2017000706A patent/MY187685A/en unknown
- 2012-04-25 EP EP21157334.0A patent/EP3933040A1/en not_active Withdrawn
- 2012-04-25 JP JP2014508494A patent/JP6320292B2/ja active Active
- 2012-04-25 WO PCT/US2012/034880 patent/WO2012148952A1/en active Application Filing
- 2012-04-25 BR BR112013027187A patent/BR112013027187A2/pt not_active Application Discontinuation
- 2012-04-25 PL PL12718549T patent/PL2702155T3/pl unknown
- 2012-04-25 HU HUE17153724A patent/HUE054129T2/hu unknown
- 2012-04-25 SG SG2013079454A patent/SG194636A1/en unknown
- 2012-04-25 US US14/111,976 patent/US9181547B2/en active Active
- 2012-04-25 CN CN202110383567.1A patent/CN113249381A/zh active Pending
- 2012-04-25 US US13/455,337 patent/US20120270928A1/en active Pending
- 2012-04-25 KR KR1020137031227A patent/KR102055172B1/ko active Active
- 2012-04-25 RS RS20210552A patent/RS61775B1/sr unknown
- 2012-04-25 EA EA201391492A patent/EA025894B1/ru not_active IP Right Cessation
- 2012-04-25 TW TW101114636A patent/TWI607016B/zh active
- 2012-04-25 SI SI201231913T patent/SI3211082T1/sl unknown
- 2012-04-25 PT PT171537244T patent/PT3211082T/pt unknown
- 2012-04-25 PT PT127185494T patent/PT2702155T/pt unknown
- 2012-04-25 DK DK17153724.4T patent/DK3211082T3/da active
- 2012-04-25 TW TW106131684A patent/TWI698445B/zh active
- 2012-04-25 MY MYPI2013003885A patent/MY175336A/en unknown
- 2012-04-25 MX MX2013012452A patent/MX2013012452A/es unknown
- 2012-04-25 EP EP12718549.4A patent/EP2702155B9/en active Active
- 2012-04-25 PL PL17153724T patent/PL3211082T3/pl unknown
- 2012-04-25 ES ES17153724T patent/ES2868950T3/es active Active
- 2012-04-25 NZ NZ717921A patent/NZ717921A/en unknown
- 2012-04-25 AU AU2012249851A patent/AU2012249851B2/en active Active
- 2012-04-25 EP EP17153724.4A patent/EP3211082B1/en active Active
- 2012-04-25 SI SI201230924A patent/SI2702155T1/sl unknown
- 2012-04-25 ES ES12718549.4T patent/ES2621863T3/es active Active
- 2012-04-25 UA UAA201312414A patent/UA115652C2/uk unknown
- 2012-04-25 LT LTEP17153724.4T patent/LT3211082T/lt unknown
- 2012-04-25 CA CA3165397A patent/CA3165397A1/en active Pending
- 2012-04-25 CA CA2833615A patent/CA2833615C/en active Active
- 2012-04-25 CN CN202110384864.8A patent/CN113151272A/zh active Pending
- 2012-04-25 KR KR1020197015054A patent/KR20190063482A/ko not_active Ceased
- 2012-04-25 CN CN201280031285.4A patent/CN103620035B/zh active Active
-
2013
- 2013-10-23 MX MX2022006595A patent/MX2022006595A/es unknown
- 2013-10-23 MX MX2022000212A patent/MX2022000212A/es unknown
- 2013-10-23 MX MX2019003090A patent/MX2019003090A/es unknown
- 2013-10-23 MX MX2019003089A patent/MX2019003089A/es unknown
- 2013-10-23 IL IL229032A patent/IL229032B/en active IP Right Grant
- 2013-10-25 CL CL2013003105A patent/CL2013003105A1/es unknown
- 2013-10-30 CO CO13257480A patent/CO6821889A2/es unknown
-
2014
- 2014-07-28 US US14/444,406 patent/US8912161B2/en active Active
-
2015
- 2015-10-14 US US14/883,055 patent/US9790496B2/en active Active
-
2017
- 2017-04-06 HR HRP20170557TT patent/HRP20170557T2/hr unknown
- 2017-04-25 CY CY20171100460T patent/CY1120304T1/el unknown
- 2017-08-29 AU AU2017219156A patent/AU2017219156B2/en active Active
- 2017-09-14 US US15/704,749 patent/US20180155719A1/en not_active Abandoned
-
2018
- 2018-02-23 HK HK18102629.5A patent/HK1243130A1/zh unknown
- 2018-04-02 JP JP2018070694A patent/JP2018121646A/ja active Pending
-
2019
- 2019-05-08 IL IL266529A patent/IL266529A/en unknown
-
2020
- 2020-01-24 US US16/751,402 patent/US20200291400A1/en not_active Abandoned
- 2020-02-26 AU AU2020201403A patent/AU2020201403A1/en not_active Abandoned
- 2020-03-18 IL IL273381A patent/IL273381A/en unknown
-
2021
- 2021-04-19 HR HRP20210616TT patent/HRP20210616T1/hr unknown
- 2021-08-18 US US17/405,482 patent/US20220098583A1/en active Pending
-
2022
- 2022-05-06 AU AU2022203067A patent/AU2022203067A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170557T2 (hr) | Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21 | |
| JP2015519891A5 (hr) | ||
| JP2014518619A5 (hr) | ||
| Paulis et al. | Novel therapeutic targets for hypertension | |
| RU2020113612A (ru) | Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2 | |
| WO2009044392A3 (en) | Novel sirna structures | |
| EA201070992A1 (ru) | МИКРО-РНК (miРНК) И МИШЕНИ СИГНАЛЬНОГО ПУТИ ДЛЯ ДИАГНОСТИЧЕСКИХ И ТЕРАПЕВТИЧЕСКИХ ЦЕЛЕЙ | |
| RU2018129378A (ru) | Способ лечения с3-гломерулопатии | |
| RU2020111236A (ru) | Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности | |
| LT3133070T (lt) | Eligliustatas (genz 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti fabri arba gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento p-450 metabolizmui | |
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| FI3431094T3 (fi) | Silloitettuja kationinvaihtopolymeerejä, koostumuksia ja käyttö hyperkalemian hoidossa | |
| SG10201909122QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| EP2446036A4 (en) | TREATMENT OF ILLNESSES ASSOCIATED WITH TUMORNEKROSE FACTOR RECEPTOR 2 (TNFR2) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST TNFR2 | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| JP2019501935A5 (hr) | ||
| EA201792541A3 (ru) | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени | |
| RU2019119129A (ru) | Способ лечения фокально-сегментарного гломерулосклероза | |
| WO2006086456A3 (en) | Combination of organic compounds | |
| WO2007017135A3 (en) | Process for the preparation of olmesartan medoxomil | |
| PH12014500943A1 (en) | Combination treatment of cancer | |
| JP2013506684A5 (hr) | ||
| EP2593547A4 (en) | TREATMENT OF DISEASES ASSOCIATED WITH DISCS LARGE HOMOLOG (DLG) BY INHIBITION OF THE NATURAL ANTISENSE TRANSCRIPTION TO DLG | |
| ME02450B (me) | POBOLJŠANO LIJEČENJE MULTlPLOG MIJELOMA | |
| JP2011510647A5 (hr) |